Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2016, Article ID 1034912, 8 pages
http://dx.doi.org/10.1155/2016/1034912
Review Article

Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks

1Division of Neurology, Amiri Hospital and Division of Neurology, Dasman Diabetes Institute, Dasman, Kuwait
2Division of Neurology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey
3King Abdullah International Medical Research Center, King Saud Ben Abdulaziz University for Health Sciences, NGHA, Riyadh, Saudi Arabia
4KFMC, Ministry of Health, Riyadh, Saudi Arabia
5MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
6Clinical Neurosciences Department, Salmaniya Medical Complex, Manama, Bahrain
7Neurology Section, King Khalid University Hospital, King Saud University and Dallah Hospital, Riyadh, Saudi Arabia
8King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
9Department of Internal Medicine, Neurology Section, Arab Medical Center and Khalidi Hospital, Amman, Jordan
10Department of Neurology (Medicine), Hamad Medical Corporation, Doha, Qatar
11Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, Málaga, Spain
12Laboratory of Experimental Neurology and Neuroimmunology, Multiple Sclerosis Center, 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
13Neurology Department, Rashid Hospital and Dubai Medical College, Dubai Health Authority, Dubai, UAE
14Department of Neurology, Neuroimmunology Unit, Hacettepe University Hospitals, Ankara, Turkey
15Merck, Intercontinental Region, Dubai, UAE
16Department of Neurology, 1st St. Petersburg State Medical University n.a. I.P. Pavlov, St. Petersburg, Russia
17Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon
18Faculty of Medicine, Ain Shams University, Cairo, Egypt
19Department of Neurosciences, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Received 5 August 2016; Accepted 14 November 2016

Academic Editor: Mauro Zaffaroni

Copyright © 2016 Raed Alroughani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Multiple Sclerosis International Federation, Atlas of MS 2013, http://www.msif.org/about-us/advocacy/atlas.
  2. M. Zakaria, D. A. Zamzam, M. A. Abdel Hafeez et al., “Clinical characteristics of patients with multiple sclerosis enrolled in a new registry in Egypt,” Multiple Sclerosis and Related Disorders, vol. 10, pp. 30–35, 2016. View at Publisher · View at Google Scholar
  3. T. Chitnis, B. Glanz, S. Jaffin, and B. Healy, “Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States,” Multiple Sclerosis, vol. 15, no. 5, pp. 627–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B. J. Wade, “Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale,” Multiple Sclerosis International, vol. 2014, Article ID 124578, 7 pages, 2014. View at Publisher · View at Google Scholar
  5. H. F. Harbo, R. Gold, and M. Tintoré, “Sex and gender issues in multiple sclerosis,” Therapeutic Advances in Neurological Disorders, vol. 6, no. 4, pp. 237–248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Trojano, G. Lucchese, G. Graziano et al., “Geographical variations in sex ratio trends over time in multiple sclerosis,” PLoS ONE, vol. 7, no. 10, Article ID e48078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Altintas, B. Najar, G. Gozubatik-Celik, and S. F. Menku, “Pregnancy data in a Turkish multiple sclerosis population,” European Neurology, vol. 74, no. 5-6, pp. 296–302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Tsui and M. A. Lee, “Multiple sclerosis and pregnancy,” Current Opinion in Obstetrics and Gynecology, vol. 23, pp. 435–439, 2011. View at Google Scholar
  9. C. Confavreux, M. Hutchinson, M. M. Hours, P. Cortinovis-Tourniaire, and T. Moreau, “Rate of pregnancy-related relapse in multiple sclerosis,” The New England Journal of Medicine, vol. 339, no. 5, pp. 285–291, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. K. A. McKay, S. Jahanfar, T. Duggan, S. Tkachuk, and H. Tremlett, “Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review,” Neurotoxicology, 2016. View at Publisher · View at Google Scholar
  11. A. Finkelsztejn, J. B. B. Brooks, F. M. Paschoal Jr., and Y. D. Fragoso, “What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 118, no. 7, pp. 790–797, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. P. Amato and E. Portaccio, “Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs,” CNS Drugs, vol. 29, no. 3, pp. 207–220, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Bove, S. Alwan, J. M. Friedman et al., “Management of multiple sclerosis during pregnancy and the reproductive years,” Obstetrics and Gynecology, vol. 124, no. 6, pp. 1157–1168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. Yalcin, Y. Yalcin, A. Yavuz, M. O. Akkurt, and M. Sezik, “Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study,” Journal of Perinatal Medicine, 2016. View at Publisher · View at Google Scholar
  15. B. Yamout, R. Alroughani, M. Al-Jumah et al., “Consensus recommendations for the diagnosis and treatment of multiple sclerosis: The Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS),” Current Medical Research and Opinion, vol. 31, no. 7, pp. 1349–1361, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Vukusic and R. Marignier, “Multiple sclerosis and pregnancy in the ‘treatment era’,” Nature Reviews Neurology, vol. 11, no. 5, pp. 280–289, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. National Institute for Health and Care Excellence, Multiple Sclerosis in aDults: Management. Clinical Guideline [CG186], October 2014, https://www.nice.org.uk/guidance/cg186.
  18. A. Wundes, R. N. Pebdani, and D. Amtmann, “What do healthcare providers advise women with multiple sclerosis regarding pregnancy?” Multiple Sclerosis International, vol. 2014, Article ID 819216, 5 pages, 2014. View at Publisher · View at Google Scholar
  19. M. Prunty, L. Sharpe, P. Butow, and G. Fulcher, “The motherhood choice: themes arising in the decision-making process for women with multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 5, pp. 701–704, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. Prescribing information for pharmacologic therapies for MS. Europe—Summaries of Product Characteristics, USA, full Prescribing Information downloaded from sponsors' product websites, http://www.medicines.org.uk/emc/.
  21. E. Lu, B. W. Wang, C. Guimond, A. Synnes, D. Sadovnick, and H. Tremlett, “Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review,” Neurology, vol. 79, no. 11, pp. 1130–1135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Sandberg-Wollheim, E. Alteri, M. S. Moraga, and G. Kornmann, “Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy,” Multiple Sclerosis Journal, vol. 17, no. 4, pp. 423–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Richman, K. Wallace, S. Liu, and B. Sperling, “Final Results from the AVONEX® (Intramuscular Interferon Beta-1a) Pregnancy Exposure Registry,” Neurology, vol. 78, no. 1, article P06.191, 2012. View at Publisher · View at Google Scholar
  24. R. S. Romero, C. Lünzmann, and J.-P. Bugge, “Pregnancy outcomes in patients exposed to interferon beta-1b,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 86, no. 5, pp. 587–589, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. P. K. Coyle, S. M. Sinclair, A. E. Scheuerle, J. M. Thorp Jr., J. D. Albano, and M. J. Rametta, “Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events,” BMJ Open, vol. 4, no. 5, Article ID e004536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Thiel, A. Langer-Gould, M. Rockhoff et al., “Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A Prospective Cohort Study from the German Multiple Sclerosis and Pregnancy Registry,” Multiple Sclerosis Journal, vol. 22, no. 6, pp. 801–809, 2016. View at Publisher · View at Google Scholar
  27. K. Hellwig, A. Haghikia, M. Rockhoff, and R. Gold, “Multiple sclerosis and pregnancy: experience from a nationwide database in Germany,” Therapeutic Advances in Neurological Disorders, vol. 5, no. 5, pp. 247–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Weber-Schoendorfer and C. Schaefer, “Multiple sclerosis, immunomodulators, and pregnancy outcome: A Prospective Observational Study,” Multiple Sclerosis, vol. 15, no. 9, pp. 1037–1042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. P. Amato, E. Portaccio, A. Ghezzi et al., “Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis,” Neurology, vol. 75, no. 20, pp. 1794–1802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Patti, T. Cavallaro, S. Lo Fermo et al., “Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?” Journal of Neurology, vol. 255, no. 8, pp. 1250–1253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Boskovic, R. Wide, J. Wolpin, D. J. Bauer, and G. Koren, “The reproductive effects of beta interferon therapy in pregnancy: A Longitudinal Cohort,” Neurology, vol. 65, no. 6, pp. 807–811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Sandberg-Wollheim, D. Frank, T. M. Goodwin et al., “Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis,” Neurology, vol. 65, no. 6, pp. 802–806, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Herbstritt, A. Langer-Gould, M. Rockhoff et al., “Glatiramer acetate during early pregnancy: a prospective cohort study,” Multiple Sclerosis Journal, vol. 22, no. 6, pp. 810–816, 2016. View at Publisher · View at Google Scholar
  34. M. Giannini, E. Portaccio, A. Ghezzi et al., “Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study,” BMC Neurology, vol. 12, article 124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. H. J. Salminen, H. Leggett, and M. Boggild, “Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes,” Journal of Neurology, vol. 257, no. 12, pp. 2020–2023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. D. Fragoso, A. Finkelsztejn, D. R. Kaimen-Maciel et al., “Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series,” CNS Drugs, vol. 24, no. 11, pp. 969–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. E. Miller, S. Rustgi, and C. Farrell, “Use of glatiramer acetate during pregnancy: offering women a choice,” Multiple Sclerosis, vol. 18, supplement 4, p. 336, 2012. View at Google Scholar
  38. A. E. Miller, “Multiple sclerosis disease-modifying therapy and pregnancy,” Multiple Sclerosis Journal, vol. 22, no. 6, pp. 715–716, 2016. View at Publisher · View at Google Scholar
  39. I. Buraga and R.-E. Popovici, “Multiple sclerosis and pregnancy: current considerations,” The Scientific World Journal, vol. 2014, Article ID 513160, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Ebrahimi, S. Herbstritt, R. Gold, L. Amezcua, G. Koren, and K. Hellwig, “Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study,” Multiple Sclerosis Journal, vol. 21, no. 2, pp. 198–205, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Hellwig, A. Haghikia, and R. Gold, “Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment,” Multiple Sclerosis Journal, vol. 17, no. 8, pp. 958–963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Haghikia, A. Langer-Gould, G. Rellensmann et al., “Natalizumab use during the third trimester of pregnancy,” JAMA Neurology, vol. 71, no. 7, pp. 891–895, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Schneider, C. E. Weber, K. Hellwig, H. Schroten, and T. Tenenbaum, “Natalizumab treatment during pregnancy—effects on the neonatal immune system,” Acta Neurologica Scandinavica, vol. 127, no. 1, pp. e1–e4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Karlsson, G. Francis, G. Koren et al., “Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis,” Neurology, vol. 82, no. 8, pp. 674–680, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. B. C. Kieseier and M. Benamor, “Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing–remitting multiple sclerosis,” Neurology and Therapy, vol. 3, no. 2, pp. 133–138, 2014. View at Publisher · View at Google Scholar
  46. J. Oh, A. Achiron, C. Chambers et al., “Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program (S24.008),” Neurology, vol. 86, no. 16, supplement, p. S24.008, 2016. View at Google Scholar
  47. K. Hellwig, S. Schimrigk, A. Chan, J. Epplen, and R. Gold, “A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis,” Journal of the Neurological Sciences, vol. 307, no. 1-2, pp. 164–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. M. De Santis, G. Straface, A. F. Cavaliere, P. Rosati, A. P. Batocchi, and A. Caruso, “The first case of mitoxantrone exposure in early pregnancy,” NeuroToxicology, vol. 28, no. 3, pp. 696–697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Gold, J. T. Phillips, E. Havrdova et al., “Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience,” Neurology and Therapy, vol. 4, no. 2, pp. 93–104, 2015. View at Publisher · View at Google Scholar
  50. M. Butler, M. L. Forte, N. Schwehr, A. Carpenter, and R. L. Kane, “Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis,” AHRQ Comparative Effectiveness Reviews 15-EHC012-EF, Agency for Healthcare Research and Quality, Rockville, Md, USA, 2015, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0077946/. View at Google Scholar
  51. A. Verhaeghe, O. M. Deryck, and L. J. Vanopdenbosch, “Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab,” Multiple Sclerosis and Related Disorders, vol. 3, no. 2, pp. 279–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. A. P. Sempere, L. Berenguer-Ruiz, and E. Feliu-Rey, “Rebound of disease activity during pregnancy after withdrawal of fingolimod,” European Journal of Neurology, vol. 20, no. 8, pp. e109–e110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. L. De Giglio, C. Gasperini, C. Tortorella, M. Trojano, and C. Pozzilli, “Natalizumab discontinuation and disease restart in pregnancy: a case series,” Acta Neurologica Scandinavica, vol. 131, no. 5, pp. 336–340, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. S. E. Hatcher, E. Waubant, B. Nourbakhsh, E. Crabtree-Hartman, and J. S. Graves, “Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment,” JAMA Neurology, vol. 73, no. 7, pp. 790–794, 2016. View at Publisher · View at Google Scholar
  55. V. Martinelli, B. Colombo, G. Dalla Costa et al., “Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning,” Multiple Sclerosis Journal, vol. 22, no. 11, pp. 1506–1508, 2016. View at Publisher · View at Google Scholar
  56. J. Fares, A. H. Nassar, S. Gebeily, F. Kobeissy, and Y. Fares, “Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study,” BMJ Open, vol. 6, no. 5, article e011210, 2016. View at Publisher · View at Google Scholar
  57. K. Hellwig, M. Rockhoff, S. Herbstritt et al., “Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses,” JAMA Neurology, vol. 72, no. 10, pp. 1132–1138, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Ragnedda, S. Leoni, M. Parpinel et al., “Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study,” Journal of Neurology, vol. 262, no. 5, pp. 1271–1277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Strijbos, S. Coenradie, D. J. Touw, and L. A. M. Aerden, “High-dose methylprednisolone for multiple sclerosis during lactation: concentrations in breast milk,” Multiple Sclerosis, vol. 21, no. 6, pp. 797–798, 2015. View at Publisher · View at Google Scholar · View at Scopus